Last year, British Columbia became the first province to introduce a mandatory biosimilar switching program for non-medical reasons.
access to new medicine
The biopharmaceutical industry is uniquely prepared to combat COVID-19.
Unfortunately, the federal government’s track record of creating reliable and accurate data systems is not good.
Developing and testing new drugs costs a lot of money.
Nobel laureate Paul Romer’s key new insight was that human capital can produce ideas.
Profit incentivizes innovation and helps fund research and development.
Delay or denial of access to life-saving drugs is a potential death sentence.